✦ LIBER ✦

Efficacy of Combined Anticholinergic Treatment and Behavioral Modification as a First Line Treatment for Nonneurogenic and Nonanatomical Voiding Dysfunction in Children: A Randomized Controlled Trial

✍ Scribed by Ayan, S.; Topsakal, K.; Gokce, G.; Gultekin, E.Y.

Book ID: 123276049
Publisher: Lippincott Williams and Wilkins
Year: 2007
Tongue: English
Weight: 216 KB
Volume: 177
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2007.02.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of tolterodine as a first-line

Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children

✍ Semih Ayan; Kemal Kaya; Kahraman Topsakal; Hakan Kilicarslan; Gokhan Gokce; Yene 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Efficacy of zinc given as an adjunct in

Efficacy of zinc given as an adjunct in the treatment of severe and very severe pneumonia in hospitalized children 2-24 mo of age: a randomized, double-blind, placebo-controlled trial

✍ Wadhwa, N.; Chandran, A.; Aneja, S.; Lodha, R.; Kabra, S. K.; Chaturvedi, M. K.; 📂 Article 📅 2013 🏛 American Society for Clinical Nutrition: 🌐 English ⚖ 256 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB